Product Description
Mechanisms of Action: SNR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Belgium | Czech | India | Ireland | Korea | Luxembourg | Malta | Netherlands | New Zealand | Pakistan | Portugal | Saudi Arabia | Singapore | Slovakia | Taiwan | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Ministry of Infrastructure and the Environment
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|